Formulation and Evaluation of Transdermal Patch of Diclofenac Sodium

Kriplani, Priyanka

doi:10.19080/gjpps.2018.04.555647

Cited by 24 publications

(20 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the time of preparing the organogel, accurately weighed LOX was dissolved in the oil phase and the aqueous phase was added slowly to this oil phase with constant stirring. Thus, the obtained organogel was evaluated for various parameters for physical appearance, pH, viscosity, spreadability, drug content, and in vitro drug diffusion profiles, utilizing methods reported in the literature [6][7][8][9]. Amongst the experimental batches, selected optimized batch organogel containing 120 mg LOX was spread over an area of 7 cm × 7 cm of nonpermeable backing layer cut into the dimensions of 8 cm × 8 cm.…”

Section: Methodsmentioning

confidence: 99%

Fabrication of an Organogel-Based Transdermal Delivery System of Loxoprofen Sodium

Katariya

Mehta

2020

The 1st International Electronic Conference on Pharmaceutics

View full text Add to dashboard Cite

Joint pain with high prevalence and yet without any specific treatment option is posing a challenge to healthcare professionals day by day. Amongst several treatment options currently utilized for arthritic joint pain are merely giving symptomatic relief rather than curative treatment. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely accessed treatment option amongst all of the options. However, their adverse effects profile is a major hurdle for their use, especially in elderly patients. The present study was focused on developing a transdermal patch of a novel NSAID Loxoprofen sodium with enhanced penetration and improved patient compliance. Pluronic lecithin organogel (PLO) was selected as transdermal drug delivery platform to enhance its penetration through skin. Moreover, the transdermal route bypasses first-pass metabolism, gastrointestinal (GI) side effects, and the necessity to administer drug orally. All of these credentials ultimately improved patient compliance. Several experimental batches (PL1 to PL8) were formulated to prepare the PLO of loxoprofen sodium. All the batches were evaluated for physical appearance, pH, viscosity, spreadability, drug content, and in vitro drug diffusion profiles. An optimized batch was selected on the basis of the obtained results. It showed sustained drug release up to 12 h. The study evidenced that similar transdermal formulations of other NSAIDs can significantly enhance current treatment scenario for joint pain. Moreover, conversion of such formulations in transdermal patches or other forms ensure sustained and reproducible transdermal flux, which can be further fabricated as bioequivalent to the oral formulations. Further studies can be designed to evaluate the clinical applicability of the formulation.

show abstract

Section: Methodsmentioning

confidence: 99%

Fabrication of an Organogel-Based Transdermal Delivery System of Loxoprofen Sodium

Katariya

Mehta

2020

The 1st International Electronic Conference on Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The prepared patches exhibited minimal water absorption rate as shown in Figure 7 which ensures stability and prevents microbial contamination. The lower moisture content even at higher relative humidity helps the patches to become completely dried and brittle film [49].…”

Section: Moisture Uptake Studymentioning

confidence: 99%

In-Silico Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain

Singh

Agarwal

Pancham

et al. 2021

CNSNDDT

View full text Add to dashboard Cite

Background: Gabapentin (GBP) is an FDA approved drug for the treatment of partial and secondary generalized seizures, apart from being used for diabetic neuropathic pain. GBP displays highly intricate mechanism of action and its inhibitory response in elevated antagonism of NMDA (N-methyl-D-aspartate receptor) receptor and thus, can be repurposed for controlling neuropathic pain. Objective: Therefore, in the present study, we have selected hBCATc (human Pyridoxal 5’-phosphate dependent branched-chain aminotransferase cytosolic) gene that is highly expressed in neuropathic stressed conditions. Thereafter, have analyzed the GBP as its competitive inhibitor by homology modeling, molecular docking, also predicting its structural alerts and pharmacokinetic suitability through ADMET. However, GBP was found to be a potential drug in controlling neuropathic pain, still it has certain critical pharmacokinetics limitations therefore, the need for its targeted delivery was required and the same was attained by designing a GBP loaded trandermal patch (TDP). Methods: A suitable and equally efficacious GBP – TDP was developed by solvent evaporation method using PVP and HPMC in ratio of 2:1 as a polymer base for reservoir type of TDP. Also, PEG 400 was used as a plasticizer and PVA (4%) was taken for backing membrane preparation and then the optimized GBP-TDP was subjected for physical characterization, optimization and ex vivo release kinetics. Methods: A suitable and equally efficacious GBP – TDP was developed by solvent evaporation method using PVP and HPMC in ratio of 2:1 as a polymer base for reservoir type of TDP. Also, PEG 400 was used as a plasticizer and PVA (4%) was taken for backing membrane preparation and then the optimized GBP-TDP was subjected for physical characterization, optimization and ex vivo release kinetics. Results and conclusion: The results showed desired specifications with uneven and flaky surface appearance giving an avenue for controlled release of the drugs with 92.34 ± 1.43% of drug release in 10 h, further suggesting that GBP-TDP can be used as an effective tool against diabetic neuropathy pain.

show abstract

“…To analyze the mechanism of the drug release rate kinetics of the dosage form, the obtained data were fitted into zero-order, first order, Higuchi and Korsmeyer-peppas release model, to study the drug release from the dosage form. [27][28][29]…”

Section: Calculation Of Model Dependent Kinetics For Prepared Patch Fmentioning

confidence: 99%

Formulation and Evaluation of Zidovudine Transdermal Patch using Permeation Enhancers

Mamatha¹,

Gadili²,

Pallavi³

2020

JYP

View full text Add to dashboard Cite

All the ingredients were weighed accurately and dissolved in a suitable solvent with continuous stirring. Then plasticizer was added to the above solution. The resultant solution was stirred for 15 min to get a clear solution and was kept aside for some time to get a bubble free solution, these solutions were casted slowly on a Teflon plate with a continuous flow to avoid bubble formation and the plates were kept at room temperature for 24 hrs. An inverted funnel was placed over the plate to control the rate of drying. (Table1) After 24 hr, formed patch was taken out and checked for its complete dryness. The dried patch was gently separated from the Teflon plate and

show abstract

Formulation and Evaluation of Transdermal Patch of Diclofenac Sodium

Cited by 24 publications

References 7 publications

Fabrication of an Organogel-Based Transdermal Delivery System of Loxoprofen Sodium

Fabrication of an Organogel-Based Transdermal Delivery System of Loxoprofen Sodium

In-Silico Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain

Formulation and Evaluation of Zidovudine Transdermal Patch using Permeation Enhancers

Contact Info

Product

Resources

About